Clinical trial
SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
NCT00299806 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00299806 |
|---|---|
| Title | SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension |
| Official title | A Multi-center, Open-label Study Assessing the Safety and Efficacy of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Aliskiren |
| Enrollment | 39 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Mar 7, 2006 |
| Last update posted | Nov 18, 2016 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: